Rare diseases
Investigational molecules
Locations
Study of Ibrutinib and Rituximab for Patients with Untreated Marginal Zone Lymphoma
FranceStudy of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations
FranceStudy Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer
FranceStudy on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer
FranceStudy of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer
FranceStudy of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)
FranceStudy of Tiragolumab, Atezolizumab, and Pembrolizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
FranceStudy of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer
FranceStudy on Neflamapimod for Patients with Dementia with Lewy Bodies
FranceStudy of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer
FranceStudy of Immunotherapy Combinations with GSK4428859, Dostarlimab, and GSK6097608 for Patients with Advanced Non-Small Cell Lung Cancer
FranceStudy on Lorlatinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer After First-line Treatment Failure
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
